Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin

Phase 3Recruiting

1 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Coronary Atherosclerosis

Conditions

Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia

Trial Timeline

Jun 1, 2026 → Oct 2, 2028

NCT ID

NCT07474649

About Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin

Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin is a phase 3 stage product being developed by Daiichi Sankyo for Coronary Atherosclerosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07474649. Target conditions include Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia.

What happened to similar drugs?

20 of 20 similar drugs in Coronary Atherosclerosis were approved

Approved (20) Terminated (2) Active (0)

✅EvolocumabHeartFlowApproved

✅Clopidogrel treatment groupYuhanApproved

✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved

✅statins, ezetimibe + Combination therapyYuhanApproved

✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved

✅PrasugrelDaiichi SankyoApproved

✅Prasugrel + ClopidogrelDaiichi SankyoApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07474649	Phase 3	Recruiting	Jun 1, 2026	Oct 2, 2028	Coronary Atherosclerosis
NCT06686615	Pre-clinical	Recruiting	Feb 12, 2025	Jan 31, 2028	Primary Hypercholesterolemiia

Competing Products

20 competing products in Coronary Atherosclerosis

See all competitors

Product	Company	Stage	Hype Score
Rosuvastatin 40mg + Placebo	HeartFlow	Pre-clinical	27
Evolocumab	HeartFlow	Approved	29
High intensity lipid lowering	HeartFlow	Pre-clinical	20
Exenatide	Eli Lilly	Phase 3	40
Clopidogrel treatment group	Yuhan	Approved	50
YH14659 + clopidogrel & aspirin	Yuhan	Phase 1	29
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibe	Yuhan	Approved	43
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)	Yuhan	Phase 3	40
statins, ezetimibe + Combination therapy	Yuhan	Approved	50
YH14659 + clopidogrel & aspirin	Yuhan	Phase 1	29
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrel	Daiichi Sankyo	Approved	43
clopidogrel + prasugrel	Daiichi Sankyo	Phase 1	21
Prasugrel	Daiichi Sankyo	Approved	43
ADP receptor inhibitors	Daiichi Sankyo	Pre-clinical	26
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	35
Prasugrel + Clopidogrel	Daiichi Sankyo	Phase 2	35
prasugrel + clopidogrel	Daiichi Sankyo	Phase 1	29
Prasugrel + Clopidogrel	Daiichi Sankyo	Approved	43
Triple oral lipid lowering treatment	Daiichi Sankyo	Phase 3	47
Placebo + Prasugrel	Daiichi Sankyo	Phase 3	40